Evaluation of trends in marijuana toxicosis in dogs living in a state with legalized medical marijuana: 125 dogs (2005–2010)

Meola, Stacy D.; Tearney, Caitlin; Haas, Sharlee A.; Hackett, Timothy B.; Mazzaferro, Elisa M.

doi:10.1111/j.1476-4431.2012.00818.x

Cited by 61 publications

(114 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, children, as well as adults and household pets (Meola, Tearney, Haas, Hackett, & Mazzaferro, 2012), may unintentionally consume edibles if they are not properly safeguarded. A review of data from the National Poison Data System from 2005 to 2011 found that decriminalization of cannabis was associated with increased reports of unintentional exposures in young children (up to 9 years of age; Wang et al, 2014).…”

Section: Challenges Of Ediblesmentioning

confidence: 99%

Tasty THC: Promises and Challenges of Cannabis Edibles

et al. 2016

View full text Add to dashboard Cite

Food products containing cannabis extract (edibles) have emerged as a popular and lucrative facet of the legalized market for both recreational and medicinal cannabis. The many formulations of cannabis extracts used in edibles present a unique regulatory challenge for policy makers. Though edibles are often considered a safe, discreet, and effective means of attaining the therapeutic and/or intoxicating effects of cannabis without exposure to the potentially harmful risks of cannabis smoking, little research has evaluated how ingestion differs from other methods of cannabis administration in terms of therapeutic efficacy, subjective effects, and safety. The most prominent difference between ingestion and inhalation of cannabis extracts is the delayed onset of drug effect with ingestion. Consumers often do not understand this aspect of edible use and may consume a greater than intended amount of drug before the drug has taken effect, often resulting in profoundly adverse effects. Written for the educated layperson and for policy makers, this paper explores the current state of research regarding edibles, highlighting the promises and challenges that edibles present to both users and policy makers, and describes the approaches that four states in which recreational cannabis use is legal have taken regarding regulating edibles.

show abstract

Section: Challenges Of Ediblesmentioning

confidence: 99%

Tasty THC: Promises and Challenges of Cannabis Edibles

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Heroin and opiates cause the most drug‐related deaths in the United States, but as there exists a specific, highly effective receptor antagonist, there is very little relevance of lipid to these overdoses 101 . Two categories of illicit drugs that might benefit from lipid infusion are the synthetic cathinones, commonly referred to as “bath salts,” and both synthetic and natural cannabinoids, 102 both of which are lipophilic. Of the cathinones, α‐pyrrolidinopentiophenone has a LogP of 3.65 and 3,4‐methylenedioxypyrovalerone has a LogP of 3.06.…”

Section: Part Iii: Clinical Futurementioning

confidence: 99%

Past, Present, and Future of Lipid Resuscitation Therapy

Fettiplace

Weinberg

2015

J Parenter Enteral Nutr

View full text Add to dashboard Cite

Lipid resuscitation therapy was identified in 1998 as an effective treatment for local anesthetic systemic toxicity in an animal model. Since the original observation, the field has progressed tremendously with successful clinical translation and expansion of use to treatment of other types of drug overdose. Recent work has expanded our understanding of the mechanism of this novel treatment, one that includes both a dynamic scavenging component and direct cardiotonic effect. In this review, we discuss the past, present, and future of lipid resuscitation therapy with a focus on our understanding of the mechanism and directions that the field is moving, both from a clinical and basic research side.

show abstract

“…Nevertheless, there are also reports on the therapeutic potential of pharmacological manipulation of the endocannabinoid system; besides addiction, this system has also been studied with respect to possible treatment of multiple sclerosis, chronic neuropathic pain, nausea and vomiting, loss of appetite, cancer or AIDS patients, psychosis, epilepsy, metabolic disorders, asthma and glaucoma (Fisar 2009;Robson 2014). In veterinary medicine attention has focused mainly on the cases of intoxication with marijuana (Donaldson 2002;Meola et al 2012). Nevertheless, there is an increasing number of reports (as yet anecdotal) on the therapeutic use of cannabinoids in small animals.…”

mentioning

confidence: 99%

The effect of the cannabinoid CB1 receptor agonist arachidonylcyclopropylamide (ACPA) on behavioural sensitisation to methamphetamine in mice

Landa¹,

Šlais²,

Máchalová³

et al. 2014

Vet. Med. - Czech

View full text Add to dashboard Cite

ABSTRACT:The psychostimulant methamphetamine (Met), similarly to other drugs of abuse, is known to produce an increased behavioural response after its repeated application (behavioural sensitisation). It has also been described that an increased response to a drug may be elicited by previous repeated administration of another drug (cross-sensitisation). We have previously shown that the CB 1 , CB 2 and TRPV (vanilloid) cannabinoid receptor agonist methanandamide, cross-sensitised to Met stimulatory effects in mice. The present study was focused on ability of the more selective and potent CB 1 receptor activator arachidonylcyclopropylamide (ACPA) to elicit cross-sensitisation to the stimulatory effects of Met on mouse locomotor behaviour in the Open field test. Male mice were randomly divided into three groups and on seven occasions (from the 7 th to 13 th day of the experiment) were administered drugs as follows:(a) n 1 : vehicle at the dose of 10 ml/kg/day; (b) n 2 : Met at the dose of 2.5 mg/kg/day; (c) n 3 : ACPA at the dose of 1.0 mg/kg/day. Locomotor behaviour in the Open field test was measured (a) after administration of vehicle on the 1 st experimental day, (b) after the 1 st dose of drugs given on the 7 th day, and (c) on the 14 th day after the "challenge doses" administered in the following manner: n 1 : saline at a dose of 10 ml/kg, n 2, 3 : Met at a dose of 2.5 mg/kg. The observed behavioural changes consisted in: (a) gradual development of habituation to the open field conditions in three consecutive tests; (b) development of behavioural sensitisation to the stimulatory effects of Met after repeated treatment; (c) insignificant effect of repeated pre-treatment with ACPA on the stimulatory effects of Met challenge dose. The results of our study give rise to the question which of the cannabinoid receptor mechanisms might be most responsible for the neuroplastic changes inducing sensitisation to the stimulatory effects of Met. Keywords

show abstract

Evaluation of trends in marijuana toxicosis in dogs living in a state with legalized medical marijuana: 125 dogs (2005–2010)

Cited by 61 publications

References 8 publications

Tasty THC: Promises and Challenges of Cannabis Edibles

Tasty THC: Promises and Challenges of Cannabis Edibles

Past, Present, and Future of Lipid Resuscitation Therapy

The effect of the cannabinoid CB1 receptor agonist arachidonylcyclopropylamide (ACPA) on behavioural sensitisation to methamphetamine in mice

Contact Info

Product

Resources

About